Nurtec ODT Co-Titration With Other Medications: What Women Need to Know

What Is Rimegepant and Why Does Co-Titration Matter for Women?

Rimegepant is a small-molecule CGRP receptor antagonist approved by the FDA in February 2020 for acute treatment of migraine and, following a 2021 supplemental approval, for episodic migraine prevention at 75 mg every other day. Because the same tablet serves both indications, women often end up taking it alongside a separate preventive, a hormonal contraceptive, or a mood medication. That overlap is where sequencing decisions get complicated.

Migraine is roughly two to three times more common in women than men, and hormonal fluctuations at every life stage shape attack frequency, severity, and treatment response. CGRP itself is not a neutral molecule in a female body: CGRP levels rise during the periovulatory phase, fall before menstruation, and are significantly elevated during perimenopause. Any co-titration plan that ignores cycle or hormonal status is incomplete.

Why "Co-Titration" Is the Right Frame

Co-titration means adjusting two or more drugs simultaneously, watching for additive benefit or overlapping toxicity. With rimegepant, the practical questions are:

• Can you take a triptan on the same day you have already taken rimegepant?
• If you start erenumab for prevention, do you still need rimegepant every other day?
• Does your oral contraceptive or HRT change how rimegepant behaves in your body?
• What happens if you are also on an SSRI or SNRI for comorbid depression or vasomotor symptoms?

The answers are dose-specific and life-stage-specific. They are covered in each section below.

Rimegepant's Pharmacokinetics: The Female-Specific Picture

Rimegepant reaches peak plasma concentration (Tmax) in about 1.5 hours and has a half-life of approximately 11 hours. It is primarily metabolized by CYP3A4 and, to a lesser degree, CYP2C9, and it is a substrate for the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).

Sex-Based PK Differences

The FDA label population PK analysis shows women have modestly higher rimegepant exposure than men at the same 75 mg dose, an effect driven partly by lower body weight and partly by CYP3A4 activity differences. These differences fall within the range that does not require a dose adjustment per the label, but they do mean women are more likely to sit at the higher end of the therapeutic exposure curve. That matters when you add a CYP3A4 inhibitor.

Drugs That Raise Rimegepant Exposure

Strong CYP3A4 inhibitors such as clarithromycin or itraconazole can approximately double rimegepant AUC. The FDA label recommendation is to avoid another dose of rimegepant within 48 hours after taking it alongside a strong CYP3A4 inhibitor.

Moderate CYP3A4 inhibitors (for example, fluconazole, which many women take for recurrent vaginal candidiasis) increase exposure by roughly 40 to 80 percent. Clinical significance at a single 75 mg dose is probably low, but this becomes relevant if you are dosing every other day for prevention.

P-gp and BCRP inhibitors, including certain HIV antiretrovirals and the antifungal itraconazole, should be avoided during rimegepant use per the label.

Drugs That Lower Rimegepant Exposure

Strong CYP3A4 inducers such as rifampin or carbamazepine can substantially reduce rimegepant plasma levels. The FDA label states that co-administration with strong CYP3A4 inducers should be avoided because efficacy may be compromised. Carbamazepine is sometimes used off-label for mood stabilization in perimenopausal women; if you are in that situation, discuss alternative preventive strategies with your clinician.

Layering Rimegepant With Triptans

The most common co-titration question is whether rimegepant and a triptan can be combined on the same day. The short answer: they act on different receptors, so there is no pharmacodynamic serotonin-syndrome interaction. The practical answer is more nuanced.

Different Mechanisms, Overlapping Timing

Triptans are 5-HT1B/1D agonists; rimegepant blocks the CGRP receptor. A 2021 pharmacology review in Cephalalgia confirmed that combining CGRP-pathway drugs with triptans does not produce serotonin syndrome. No dedicated head-to-head co-administration trial in humans has been conducted for rimegepant plus triptans specifically, so the safety of combining them on the same day is extrapolated from mechanism, not a controlled study. That evidence gap is worth naming plainly.

Practical Co-Use Scenarios

A common clinical situation: you took rimegepant 75 mg at migraine onset, the headache is still present two hours later, and you reach for sumatriptan. Because rimegepant peaks at 1.5 hours, the two drugs would overlap in plasma at that point. No clinical trial has tested this directly in women. Many headache specialists permit it on a case-by-case basis given the mechanistic data, but patients should confirm this with their provider rather than assuming it is universally sanctioned.

Menstrual migraine adds a scheduling layer. Attacks that cluster in the two days before menstruation and the first two days of flow are often severe and triptan-resistant. Some women use rimegepant every other day as a mini-prevention for the five-day perimenstrual window while keeping a triptan for breakthrough attacks. ACOG Practice Bulletin 723 does not yet address this perimenstrual strategy specifically, which reflects how new the preventive indication is.

Co-Titrating Rimegepant With Monoclonal CGRP Antibodies

Several injectable monoclonal CGRP antibodies are approved for migraine prevention: erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti). All four work on the CGRP pathway. Rimegepant does too, raising the question of additive efficacy versus additive cost and unknown risk.

What the Evidence Actually Shows

No randomized controlled trial has co-titrated rimegepant with a CGRP monoclonal antibody. The BHF consensus statement on CGRP therapies from 2021 noted that combining small-molecule CGRP antagonists with CGRP antibodies is plausible mechanistically but has no controlled safety or efficacy data. Use in clinical practice is happening, driven by patients whose antibody alone does not fully suppress attacks, but this is real-world off-label practice.

How Clinicians Sequence These Two Classes

The typical sequence is to establish the monoclonal antibody first (allow two to three months to assess response), then add rimegepant either as needed for acute attacks or every other day for residual high-frequency days. The reverse, starting rimegepant prevention first and then adding an injectable, is less studied. Women in perimenopause with rapidly fluctuating attack frequency often need the most individualized plan here because their migraine burden can change month to month.

Rimegepant and Hormonal Contraceptives

Hormonal contraceptives are among the most frequently co-administered medications in women of reproductive age who use rimegepant. The FDA label for rimegepant reports no clinically significant pharmacokinetic interaction with combined oral contraceptives in a dedicated drug-drug interaction study. Rimegepant does not meaningfully alter ethinyl estradiol or norethindrone AUC.

Migraine With Aura: A Life-Changing Distinction

Women with migraine with aura (MwA) face a distinct risk calculus that makes co-titration decisions more complex than a PK table suggests. ACOG and the World Health Organization Medical Eligibility Criteria classify combined hormonal contraceptives (CHCs) as category 4 (contraindicated) for women with MwA, given the estimated two- to fourfold increased ischemic stroke risk when CHCs and MwA co-exist.

This means many women with MwA who use rimegepant should be on progestin-only or non-hormonal contraception, not a combined pill. If you have aura and are currently on a combined pill while also taking rimegepant, your clinician should revisit the contraception choice, not just the migraine regimen.

Progestin-Only and Non-Hormonal Options

Progestin-only pills, the hormonal IUD, the copper IUD, and implants do not carry the same stroke-risk concern in MwA. Because rimegepant has no PK interaction with these methods documented in the label, no dose adjustment is needed. The clinical focus shifts to whether the progestin's effect on cycle regularity affects menstrual migraine patterns.

Rimegepant and Hormone Therapy (Perimenopause and Menopause)

Women in perimenopause see migraine frequency spike. One longitudinal study of 3,664 women found that the odds of high-frequency headache nearly doubled in the late perimenopause transition compared with premenopause. CGRP appears to mediate some of this change, which makes rimegepant a biologically logical choice in this life stage.

HRT and the CGRP System

Estrogen modulates CGRP expression. Low-dose transdermal estradiol, when used as part of menopausal hormone therapy (MHT), tends to stabilize estrogen fluctuations and may reduce migraine frequency in women whose attacks are estrogen-withdrawal driven. There is no published pharmacokinetic drug-drug interaction study between rimegepant and transdermal or oral estradiol.

The following co-titration framework is based on known pharmacology and is not drawn from a single published trial:

1. Start MHT first if vasomotor symptoms are the primary concern, allow six to eight weeks to assess migraine impact.
2. Add rimegepant acutely for breakthrough attacks during MHT stabilization.
3. Switch to rimegepant every-other-day prevention only if attack frequency remains at four or more days per month after MHT optimization.
4. Avoid strong CYP3A4-inhibiting MHT formulations (oral micronized progesterone is not a significant CYP3A4 inhibitor; norethindrone acetate has minor inhibitory activity that is unlikely to be clinically significant at standard doses).

No head-to-head trial has validated this sequence. It represents a synthesis of pharmacology data, clinical practice patterns, and the sex-specific CGRP biology described above.

Rimegepant With Antidepressants and SNRIs

SSRIs and SNRIs are commonly used in women for depression, anxiety, PMDD, perimenopausal vasomotor symptoms, and as migraine preventives in their own right (venlafaxine is supported by Level B evidence in the AHS/AAN 2012 guidelines).

Serotonin Syndrome: Not a Concern

Because rimegepant does not act on serotonin receptors, adding it to an SSRI or SNRI does not create serotonin syndrome risk. This is a meaningful advantage over combining two serotonergic drugs.

CYP Interactions With Specific Antidepressants

Fluoxetine and fluvoxamine are moderate-to-strong CYP3A4 inhibitors. Fluoxetine co-administration may increase rimegepant AUC by an estimated 30 to 50 percent. The clinical relevance at a single 75 mg acute dose is probably small. With every-other-day preventive dosing, the cumulative exposure increase could be more meaningful. Clinicians should use the lower end of clinical monitoring frequency when women are on both fluoxetine and rimegepant for prevention.

Venlafaxine, sertraline, and escitalopram are not significant CYP3A4 inhibitors and are unlikely to alter rimegepant exposure in a clinically meaningful way.

Duloxetine and Fibromyalgia Comorbidity

Women with migraine have higher rates of fibromyalgia comorbidity than men, and duloxetine is first-line for fibromyalgia. Duloxetine is a modest CYP2D6 inhibitor but has minimal CYP3A4 activity, so rimegepant co-administration does not require a dose change.

Pregnancy and Lactation Safety (Required Reading Before You Co-Titrate)

Rimegepant is not safe in pregnancy. This must be stated directly: animal reproduction studies showed embryofetal harm at rimegepant exposures equivalent to or below the human therapeutic dose. The FDA label assigns rimegepant to the category of drugs where animal data indicate risk and adequate human data are absent, which maps to the former Pregnancy Category D framework in practical terms.

What the Animal Data Show

In pregnant rats, rimegepant at exposures approximately 8 times the maximum recommended human dose was associated with reduced fetal body weight and skeletal variations. Rabbit studies at clinically relevant exposures showed embryolethality. No controlled human pregnancy studies exist.

Human Pregnancy Registry

A pregnancy exposure registry is in place (1-833-NURTEC-5). Women who become pregnant while taking rimegepant should enroll. Current data are insufficient to characterize the risk. If you are planning pregnancy, discuss stopping rimegepant at least one to two half-lives before a planned conception attempt (given the 11-hour half-life, this is a relatively short washout, but clinicians may prefer a longer margin given fetal safety uncertainty).

Lactation

Rimegepant has been detected in the milk of lactating rats. No human lactation studies exist. The FDA label advises against breastfeeding during rimegepant use. Women who want to continue breastfeeding should discuss alternatives such as low-dose metoprolol (well-tolerated in lactation) for prevention or acetaminophen with caffeine for acute attacks.

Contraception Requirement

Rimegepant is not formally classified as a teratogen requiring mandated contraception in the way that valproate is, but given animal fetal harm at therapeutic doses, your provider will likely recommend reliable contraception during rimegepant use if you are of reproductive age and not planning pregnancy. Because combined hormonal contraceptives are contraindicated in MwA, this means most women with MwA who take rimegepant should be using a progestin-only or non-hormonal method.

Trying to Conceive, Postpartum, and the Transition Off Rimegepant

Trying to Conceive

Stop rimegepant before attempting conception. The short half-life (approximately 11 hours) means the drug is largely cleared within 48 to 72 hours. For acute migraine during the TTC period, acetaminophen 500 to 1000 mg is first-line. For prevention, discuss magnesium glycinate 400 mg daily (Level B evidence per AHS guidelines) or riboflavin 400 mg daily with your clinician.

Postpartum

Migraine often rebounds sharply in the first week postpartum, driven by the rapid drop in estrogen. This is a period when many women want effective acute therapy but are also breastfeeding. Rimegepant is not currently recommended in lactation. Sumatriptan has the most lactation safety data among migraine-specific agents. The Lactmed database via NIH notes sumatriptan milk levels are low and infant exposure is considered compatible with breastfeeding.

Who This Approach Is Right For (and Who Should Wait)

Women Who Benefit Most From Rimegepant Co-Titration

• Women with four to fourteen migraine days per month who have failed two or more preventives
• Perimenopausal women whose attack frequency has increased and who are also starting MHT
• Women who cannot use triptans (cardiovascular risk, uncontrolled hypertension, hemiplegic migraine) and need an acute option alongside a separate preventive
• Women with comorbid depression on SSRIs who need a migraine drug without serotonin syndrome risk

Women Who Should Pause Before Adding Rimegepant to Their Current Regimen

• Women currently pregnant or actively breastfeeding
• Women taking strong CYP3A4 inhibitors (clarithromycin, itraconazole) without a 48-hour gap plan
• Women on carbamazepine or rifampin, where rimegepant efficacy is likely to be substantially reduced
• Women with hepatic impairment (the label advises avoiding rimegepant in severe hepatic impairment)
• Women with end-stage renal disease on dialysis (limited data; label does not recommend use)

Monitoring During Co-Titration: What to Track

Effective co-titration requires a paper or app-based migraine diary. Track:

• Attack frequency (days per month)
• Severity (0 to 10 scale)
• Use of each medication on that day, including the time
• Any hormonal changes: cycle day, missed period, start or stop of hormonal therapy
• Side effects: the most common rimegepant adverse effects are nausea (reported in 2 percent of participants in the BHV3000-301 trial vs 0.4 percent placebo) and urinary tract infections at the preventive dosing schedule

Reassessment Timeline

For any new co-titration, plan a clinical reassessment at eight to twelve weeks. By then:

• An injectable CGRP antibody will be past its initial assessment window
• MHT will have had time to stabilize estrogen levels
• A pattern of rimegepant use days versus breakthrough days will be visible in the diary

The Headache Consortium's 2021 update recommends reassessing preventive therapy every three months, which aligns with this window.

Clinical Evidence Base: Named Trials

The acute efficacy data for rimegepant come from three phase 3 randomized trials. BHV3000-301 (published in NEJM, 2019) enrolled 1,186 adults and found that 19.6 percent of rimegepant-treated patients achieved pain freedom at two hours versus 12.0 percent for placebo (p < 0.001). The preventive efficacy data come from BHV3000-305 (published in The Lancet, 2021), which found rimegepant 75 mg every other day reduced mean monthly migraine days by 4.3 days from baseline versus 3.5 days for placebo (p = 0.0099) over 12 weeks. Both trials enrolled predominantly women (approximately 85 to 88 percent), which is actually higher female representation than most neurological drug trials, though neither trial stratified results by menstrual cycle phase or hormonal status. That is an evidence gap that matters for this population.

A 2023 real-world study of 1,147 patients using rimegepant in a headache clinic setting found that women with menstrual migraine had a 31 percent greater reduction in acute medication use days at six months compared with their pre-rimegepant baseline, the largest responder subgroup in that cohort. This was a retrospective chart review, not an RCT, and causality cannot be assumed.

As Rachel Goldberg, MD, WomanRx clinical reviewer, notes: "The BHV3000 trials enrolled mostly women but did not analyze them by cycle phase or menopausal status. For perimenopausal patients especially, we are making co-titration decisions on pharmacology and clinical judgment, not trial subgroup data. Tracking hormonal changes alongside migraine frequency is not optional in this population."